Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Given the daily volume I guess most haven’t traded this ticker. Time will tell good dd though
$AAGH is Brand New >>> Item 5.01 Changes In Control of the Registrant
A change of control took place on January 19, 2017 from Jay Hooper, the former current officer and director of the Company and its majority shareholder. Control was obtained by the sale of 16,155,746,000 shares of Company common stock from Mr. Hooper to an investor group led by Mike Q. Wang. The allocation of shares between Mr. Wang and the various investors is being determined at this time. It is anticipated that new management will be put in place, but there has been no decision as of the date of this Current Report on Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: January 19, 2017
CROWN MARKETING
By: /s/ Jay Hooper
Name: Jay Hooper
Title: Chief Executive Officer
STRAIGHT from Q >>> FDA APPROVED Cancer Treatment Equipment/Cardio Vascular Detection Devices >> The Company under the new management will focus its business in the health related industry. The Company’s Chairman and president, Mike Wang, is the owner of several health related businesses below with which The Company is evaluating the possibilities of forming several joint ventures. The Company might effectuate the joint ventures using stocks.
1.
Health & Beauty Group Inc. It is a California company in the business of R &D and sale of vitamins and nutritional supplements. It owns more than 20 formulas and engages contract manufacturers to make these products. The company has built up solid sales records both in the US as well as in China.
2.
Pro Health Inc., a Tennessee company organized in 2016. It entered into a Sales Agreement with Provision Healthcare , LLC, a Tennessee limited liability company, in the selling of ProNova Equipment, which is a Proton Treatment device used in the treatment of cancer. Other than the sale of equipment, Pro Health will also be providing Total Solution Services related with the use of the Equipment.
3.
Sales Agreement between Mike Wang and Dr. William Fang for the marketing and sales of Dr. Fang’s early detection system of Cardio Vascular diseases. The device provides unique 3D imaging for the Cardio Vascular conditions for patients and has already won approval of US FDA. It has very positive significance in helping preventing heart attacks, which are the number one killer in the US as well as in the world.
Incredible FDA Approved ProNova Protein Therapy Equipment >> http://provisionhealthcare.com/proton-therapy/proton-therapy-system/
Pro Health Inc., a Tennessee company organized in 2016. It entered into a Sales Agreement with Provision Healthcare , LLC, a Tennessee limited liability company, in the selling of ProNova Equipment, which is a Proton Treatment device used in the treatment of cancer. Other than the sale of equipment, Pro Health will also be providing Total Solution Services related with the use of the Equipment.
How BIG is Partner...Provision Healthcare to Develop $100 Million Advanced Cancer Treatment Center in New Orleans
Provision Healthcare to Develop $100 Million Advanced Cancer Treatment Center in New Orleans
0
Provision Healthcare to Develop $100 Million Advanced Cancer Treatment Center in New Orleans
Louisiana Proton Therapy Center will be housed on University Medical Center campus in city’s biomedical corridor
NEW ORLEANS — Today, Gov. John Bel Edwards and Provision Healthcare CEO Terry Douglass announced the company and its partners will make a $100 million capital investment and build a 30,000-square-foot Louisiana Proton Therapy Center in the New Orleans biomedical corridor. Deploying advanced technology that produces far fewer side effects than conventional radiation treatments for cancer, Provision plans to develop the center on the University Medical Center campus on Canal Street.
Provision Healthcare is pursuing a partnership with University Medical Center New Orleans, LCMC Health and LSU Health Sciences Center New Orleans. The project will create 60 new direct jobs with an average annual salary of $100,000, plus benefits. Louisiana Economic Development estimates the project also will result in 63 new indirect jobs, for a total of more than 120 new jobs in the New Orleans area.
With only two dozen proton therapy centers in operation in the U.S. – and the nearest centers at Willis-Knighton Health System in Shreveport, Louisiana, and MD Anderson Cancer Center in Houston – Provision will introduce a more-efficient prototype facility in New Orleans, where the company and local partners expect to draw a wide range of regional, out-of-state and out-of-country patients. The broad geographic base is expected to drive greater medical tourism to New Orleans and increase the city’s profile as a healthcare destination.
“Every year, nearly two million Americans are diagnosed with cancer, and they frequently face life-threatening consequences,” Gov. Edwards said. “Of these patients, several hundred thousand are good candidates for proton therapy and would greatly benefit from these innovative treatments. Yet fewer than 10 percent of those patients can now be served by existing proton therapy centers. We’re proud that New Orleans will be a vital part of the solution for increasing this life-saving capacity. We’ll see our largest city become a stronger healthcare magnet because of this center. Most importantly, we will see more lives saved in Louisiana.”
Based in the Knoxville, Tennessee, area, Provision Healthcare was formed in 2005 with a goal of furnishing comprehensive, community-based solutions in innovative cancer care. Dr. Terry Douglass, a Ph.D. in electrical engineering, founded the firm after leading companies (EG&G Ortec, CTI Molecular Imaging) that pioneered medical imaging technologies, including PET – positron emission tomography – and PET’s combination with CT – computer-assisted tomography – that became leading tools for early cancer detection.
“Provision chose to expand and invest in Louisiana because of the strength of the healthcare community in Louisiana and New Orleans, and the support and collaboration received from local and state authorities,” Douglass said. “We believe that proton therapy can benefit Louisiana and New Orleans, which has some of the highest cancer-incidence rates in the country. In addition, we are particularly excited about the possibility of working with LCMC and LSU Health and the vision that they have to provide world-class cancer care in New Orleans.”
Provision plans to break ground on the Louisiana Proton Therapy Center before the end of 2017. Following a two-year construction phase, the center will begin seeing patients by late 2019.
“As the region’s leading academic medical center, access to cutting-edge technology and research is a core part of our mission at University Medical Center New Orleans,” said CEO Gregory C. Feirn of LCMC Health. “This proton therapy center can provide next-generation cancer treatment to our community and region – an innovative tool in our fight against cancer and in solidifying UMC’s role in destination healthcare.”
“Cancer incidence and mortality rates among men and women in Louisiana are worse than the national rates for all cancers combined, and cancer remains the second-leading cause of death here,” said Chancellor Larry H. Hollier, M.D., of LSU Health Sciences Center New Orleans. “In putting this innovative technology to work for our patients, we hope to make great strides in reducing those stark statistics and greatly improve both their quantity and quality of life.”
To secure the project, LED offered the company a competitive incentive package that includes a $1 million performance-based grant, payable in five annual installments beginning in 2020, and the comprehensive workforce solutions of LED FastStart® – the nation’s No. 1 state workforce training program. In addition, Provision Healthcare is expected to utilize Louisiana’s Quality Jobs Program.
“We are thrilled that Provision has decided to bring their company to New Orleans,” Mayor Mitch Landrieu said. “This is another sign of New Orleans’ growing economy and business attraction efforts. Provision will be a great addition to our healthcare industry and biomedical corridor, will create jobs, and will advance cancer treatment to help people in a real way.”
Provision Healthcare and the Louisiana Proton Therapy Center have engaged The HWH Group to pursue federal New Markets Tax Credits that support redevelopment in the city’s biomedical corridor. Beyond the healthcare partnerships, a central factor in selecting the University Medical Center site is its location in a qualified U.S. census tract. The location qualifies the proton therapy cancer center development for federal financing through the New Markets Tax Credit program.
“We are delighted to welcome Provision to New Orleans,” said President and CEO Quentin Messer of the New Orleans Business Alliance. “This project underscores the unique potential of the University Medical Center and LSU Health Sciences Center and other local research institutions and healthcare providers to spur bio-related economic growth in New Orleans and throughout the region. New Orleans’ unparalleled, world-class research innovation, hospitality and teamwork made this project a reality. NOLABA’s support of the Louisiana Proton Therapy Center is only beginning and we cannot wait for the first patient testimonials.”
“GNO Inc. is delighted to welcome Provision Healthcare to greater New Orleans,” said GNO Inc. President and CEO Michael Hecht. “Provision Healthcare is an exciting manifestation of our destination healthcare strategy, whereby people from outside of New Orleans come here to seek critical care, and spend time and money. We look forward to working with our healthcare providers and Provision to ensure their success, and to continue to grow our biomedical sector in greater New Orleans.”
###
About Provision Healthcare
Headquartered in Knoxville, Tennessee, Provision Healthcare LLC was formed in 2005 to develop innovative healthcare solutions focused on improving patient care and clinical outcomes and developing support for research, education and charitable causes. Provision brings expertise in development, management and startup of cancer centers and proton centers, utilizing the state-of-the-art ProNova SC360 proton therapy system. This unique expertise and experience – combined with an innovative, entrepreneurial approach – have propelled Provision toward a position of industry leadership with respect to both cancer care and proton therapy.
Prospective patients can learn more about proton therapy by clicking below:
CONTACTS:
Gary Perilloux
Louisiana Economic Development – Baton Rouge, LA
Gary.Perilloux@la.gov
(225) 342-3437
Nancy Howard
Provision Healthcare – Knoxville, TN
nancy.howard@provisionproton.com
(865) 603-0865
FDA Approved Cardiovascular Device/Cancer Treatment Equipment Sales and Repairs as well!!
So far its acting like it did yesterday. Waves of volume throughout the day to push it higher. I don't have l2 but hopefully its still thin above .02
100%, I sent a complaint to IT. They are looking into it.
Bids building. About to pop again for new 52 wk highs
Do ppl even look at the bid ask when they dump LOL
Good morning. $AAGH
Lets see if she can hit .10 tomorrow. Keep the flippers out it should do pretty good. Not much of ihub is even in on this yet. Amazing day!
Awareness tomorrow we break .03/.04/.05....Beast mode
Petey she's a real special play, loaded with $$ type DD
.03's up on the ask Cheeky!! AAGH
$765,000 Stock Purchase Agreement, the Company agreed to purchase 51% of common shares of the Seller, for an aggregate purchase price of $765,000, which consisting of 63,750,000 outstanding shares of the Company’s common stock at $0.012 per share.
AUDITED FINS COMING...On January 29, 2018, we engaged Sadler, Gibb & Associates, LLC ( “ Sadler Gibb ” ) as our independent registered public accounting firm to audit the Company ’ s consolidated financial statements as of June 30, 2018 and for the year then ended. Sadler Gibb will be performing reviews of the unaudited consolidated quarterly financial statements to be included in the Company ’ s quarterly reports on Form 10-Q for the year ended June 30, 2018 as well as going forward.
During each of the Company ’ s two most recent fiscal years and through the date of this report, (a) the Company has not engaged Sadler Gibb as either the principal accountant to audit the Company ’ s financial statements, or as an independent accountant to audit a significant subsidiary of the Company and on whom the principal accountant is expected to express reliance in its report; and (b) the Company or someone on its behalf did not consult Sadler Gibb with respect to (i) either: the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on the Company ’ s financial statements, or (ii) any other matter that was either the subject of a disagreement or a reportable event as set forth in Items 304(a)(1)(iv) and (v) of Regulation S-K.
ITEM 9.01 Financial Statements and Exhibits.
Exhibit 16.1: Letter from TAAD LLP dated Feburary 2, 2018 to the Securities and Exchange Commission
Break .05, I think a whole new level of buying steps in.
10k left @ .025, $0.05 coming EOD imo
January 04, 2018, America Great Health (the “Company”) entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) with Health & Beauty Group, Inc. (the “Seller”), a California Corporation focus on manufacuring and distrubution of health supplements and costmetic beauty proucts. Pursuant to the Stock Purchase Agreement, the Company agreed to purchase 51% of common shares of the Seller, for an aggregate purchase price of $765,000, which consisting of 63,750,000 outstanding shares of the Company’s common stock at $0.012 per share.
Health & Beauty Group Inc. It is a California company in the business of R &D and sale of vitamins and nutritional supplements. It owns more than 20 formulas and engages contract manufacturers to make these products. The company has built up solid sales records both in the US as well as in China.
Pro Health Inc., a Tennessee company organized in 2016. It entered into a Sales Agreement with Provision Healthcare , LLC, a Tennessee limited liability company, in the selling of ProNova Equipment, which is a Proton Treatment device used in the treatment of cancer. Other than the sale of equipment, Pro Health will also be providing Total Solution Services related with the use of the Equipment.
FDA APPROVAL BABY...Sales Agreement between Mike Wang and Dr. William Fang for the marketing and sales of Dr. Fang’s early detection system of Cardio Vascular diseases. The device provides unique 3D imaging for the Cardio Vascular conditions for patients and has already won approval of US FDA. It has very positive significance in helping preventing heart attacks, which are the number one killer in the US as well as in the world
Yep, it's SUPER THIN!!! no shares on L2.
The Acquisition of the Health and Beauty Group brings revenues instantly from the North American/Chinese markets. Plus big partnerships with Pro Health for Cancer Equipment and a Partnership with Dr. Fang for his FDA Approved Cardiovascular Day Detection for Heart Attacks
Health & Beauty Group Inc. It is a California company in the business of R &D and sale of vitamins and nutritional supplements. It owns more than 20 formulas and engages contract manufacturers to make these products. The company has built up solid sales records both in the US as well as in China.
2.
Pro Health Inc., a Tennessee company organized in 2016. It entered into a Sales Agreement with Provision Healthcare , LLC, a Tennessee limited liability company, in the selling of ProNova Equipment, which is a Proton Treatment device used in the treatment of cancer. Other than the sale of equipment, Pro Health will also be providing Total Solution Services related with the use of the Equipment.
3.
Sales Agreement between Mike Wang and Dr. William Fang for the marketing and sales of Dr. Fang’s early detection system of Cardio Vascular diseases. The device provides unique 3D imaging for the Cardio Vascular conditions for patients and has already won approval of US FDA. It has very positive significance in helping preventing heart attacks, which are the number one killer in the US as well as in the world.
Does the company have any revenue or sales or partnerships yet?
There's no convertible debt, so she moves fast.
Yes, CEO holds 16-18B, plus the other insiders. These guys are holding for dollars.
OS is 20,236,021,800 (from last 10Q)?
Hard to get shares, CEO/Insiders Own it All!!
STRAIGHT from Q, The Company under the new management will focus its business in the health related industry. The Company’s Chairman and president, Mike Wang, is the owner of several health related businesses below with which The Company is evaluating the possibilities of forming several joint ventures. The Company might effectuate the joint ventures using stocks.
1. Health & Beauty Group Inc. It is a California company in the business of R &D and sale of vitamins and nutritional supplements. It owns more than 20 formulas and engages contract manufacturers to make these products. The company has built up solid sales records both in the US as well as in China.
2. Pro Health Inc., a Tennessee company organized in 2016. It entered into a Sales Agreement with Provision Healthcare , LLC, a Tennessee limited liability company, in the selling of ProNova Equipment, which is a Proton Treatment device used in the treatment of cancer. Other than the sale of equipment, Pro Health will also be providing Total Solution Services related with the use of the Equipment.
3. Sales Agreement between Mike Wang and Dr. William Fang for the marketing and sales of Dr. Fang’s early detection system of Cardio Vascular diseases. The device provides unique 3D imaging for the Cardio Vascular conditions for patients and has already won approval of US FDA. It has very positive significance in helping preventing heart attacks, which are the number one killer in the US as well as in the world.
The Company is also planning to conduct acquisition. Mike Wang has approached several health related companies in China and met the management of potential acquisition targets. Rapid economic advances in China in the last thirty years have greatly improved the living standards in China. This in turn brings demand in healthcare products and services. Company feels strongly that despite the challenges of cross border business, we might be able to acquire some good growth companies and bring good values to our stockholders.
Their Financials are Loaded with Amazing Due Diligence..
Can't believe people aren't seeing this. You gave them plenty heads up. There's the bid support
Break .01 and I think she's flies.
There's no shares under .01, absolutely locked up Share Structure.
Yep the bids a little low though.Volume will fix that.
Current Report Filing (8-k)Source: Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 2nd, 2018
America Great Health
(Exact name of registrant as specified in charter)
WYOMING
(State or other jurisdiction of incorporation)
0-27873
98-0178621
(Commission File Number)
(IRS Employer Identification No.)
1609 W Valley Blvd., #338,
Alhambra, CA 91803
28277
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (626) 576-1299
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
? Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
? Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
? Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
? Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1934 (§240.12b-2 of this chapter)
Emerging growth company ? .
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ?
ITEM 4.01 Change in Registrant’s Certifying Accountant.
(a) Dismissal of Independent Registered Public Accounting Firm.
NEW AUDITOR/AUDITED FINANCIALS JUNE 30/2018....On January 28 2018, America Great Health (the “Company ” ) dismissed TAAD LLP ( “ TAAD ” ) as the Company’s independent registered public accounting firm.
The TAAD reports on the Company ’ s financial statements for the years ended June 30, 2017 and 2016 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.
During the Company ’ s years ended June 30, 2017 and 2016 and through January 28 2018, (i) there were no disagreements with TAAD on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to TAAD ’ s satisfaction, would have caused TAAD to make reference to the subject matter of such disagreements in its reports on our consolidated financial statements for such years, and (ii) there were no reportable events as defined in Item 304(a)(1)(v) of Regulation S-K.
The Company has provided TAAD with a copy of the foregoing disclosures and requested that TAAD furnish a letter to the Securities and Exchange Commission stating whether or not it agrees with the above statements. A copy of such letter is filed as Exhibit 16.1 to this Current Report on Form 8-K.
(b) Engagement of New Independent Registered Public Accounting Firm.
On January 29, 2018, we engaged Sadler, Gibb & Associates, LLC ( “ Sadler Gibb ” ) as our independent registered public accounting firm to audit the Company ’ s consolidated financial statements as of June 30, 2018 and for the year then ended. Sadler Gibb will be performing reviews of the unaudited consolidated quarterly financial statements to be included in the Company ’ s quarterly reports on Form 10-Q for the year ended June 30, 2018 as well as going forward.
During each of the Company ’ s two most recent fiscal years and through the date of this report, (a) the Company has not engaged Sadler Gibb as either the principal accountant to audit the Company ’ s financial statements, or as an independent accountant to audit a significant subsidiary of the Company and on whom the principal accountant is expected to express reliance in its report; and (b) the Company or someone on its behalf did not consult Sadler Gibb with respect to (i) either: the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on the Company ’ s financial statements, or (ii) any other matter that was either the subject of a disagreement or a reportable event as set forth in Items 304(a)(1)(iv) and (v) of Regulation S-K.
ITEM 9.01 Financial Statements and Exhibits.
Exhibit 16.1: Letter from TAAD LLP dated Feburary 2, 2018 to the Securities and Exchange Commission.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.
AMERICA GREAT HEALTH
Date: February 2 nd , 2018
By: /s/ Mike Wang
Name: Mike Wang
Title: President
Huge Stock Purchase $765,000/Acquisition.....Stock Purchase Agreement (the “Stock Purchase Agreement”) with Health & Beauty Group, Inc.....Current Report Filing (8-k)Source: Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 04, 2018
America Great Health
(Exact name of registrant as specified in charter)
WYOMING
(State or other jurisdiction of incorporation)
0-27873
98-0178621
(Commission File Number)
(IRS Employer Identification No.)
1609 W Valley Blvd., #338,
Alhambra, CA 91803
28277
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (626) 576-1299
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
? Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
? Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
? Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
? Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1934 (§240.12b-2 of this chapter)
Emerging growth company ? .
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ?
Item 1.01 Entry Into a Material Definitive Agreement.
On January 04, 2018, America Great Health (the “Company”) entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) with Health & Beauty Group, Inc. (the “Seller”), a California Corporation focus on manufacuring and distrubution of health supplements and costmetic beauty proucts. Pursuant to the Stock Purchase Agreement, the Company agreed to purchase 51% of common shares of the Seller, for an aggregate purchase price of $765,000, which consisting of 63,750,000 outstanding shares of the Company’s common stock at $0.012 per share.
The foregoing description of the Stock Purchase Agreement and its terms is qualified in its entirety by the full text of the agreement, which is filed as Exhibit 10.1 to, and incorporated by reference in, this report.
Item 9.01 Financial Statements and Exhibits.
The exhibit listed in the following Exhibit Index is filed as part of this report:
10.1 Stock Purchase Agreement dated January 04, 2018
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.
AMERICA GREAT HEALTH
Date: January 04, 2018
By: /s/ Mike Wang
Name: Mike Wang
Title: President
HIRED NEW COO....Current Report Filing (8-k)Source: Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 08, 2018
America Great Health
(Exact name of registrant as specified in charter)
WYOMING
(State or other jurisdiction of incorporation)
0-27873
98-0178621
(Commission File Number)
(IRS Employer Identification No.)
1609 W Valley Blvd., #338,
Alhambra, CA 91803
28277
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code: (626) 576-1299
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
? Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
? Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
? Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
? Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective January 02, 2018, the Board of Directors (the "Board") of America Great Health (the "Company") determined that it was in the best interest of the Company to hire a new Chief Operating Officer ("COO"). Accordingly, the Board approved the appointment of Andy Weichu Sheng as the Company's COO.
Mr. Sheng, age 62, has 30 years extensive experiences in business management and operation. Prior to current positions, Mr. Sheng served as President at Tradeshowusa.com since 2002; and Chief Executive Officer at Bizusa.us since 2013, Mr. Sheng served as President at Shoes Expert; during 1998 to 2002, Mr. Sheng served as President and Chief Executive Officer at Hemei Security; Mr. Sheng also served as President at SICO Group General Electric China Sole Distributor for three years since 1990.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.
AMERICA GREAT HEALTH
Date: January 08, 2018
By: /s/ Mike Wang
Name: Mike Wang
Title: President
Easily worth $1.00, I'll take $0.10+..FDA APPROVED PRODUCTS, MEDICAL EQUIPMENT.
Followers
|
52
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1937
|
Created
|
10/09/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |